BiotechBlog partner DrugPatentWatch is proud to announce the availability of a new report in the reports store.
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator brands in the global biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory pathway. Funds are flowing into the sector and many new partnership agreements signed. Everything in the biosimilar garden might look rosy, but what is the reality?
Biosimilar sales of $16+ billion were forecast in the EU and US alone for 2011.This estimate turned out to be 50-times too high. Does publication of the long-awaited guidance on the US Biologics Price Competition and Innovation Act mean a new dawn for biosimilars, or another false one? Written with the understandable detail and objectivity you need, Biosimilars: Current Situation & Future Prospects, Worldwide provides the answers, including:
- On the basis of several years market experience in Europe and Japan, where and with which biosimilars has most and least success been achieved, and why.
- Complexities of biological patents.
- The big controversies with biosimilars explained: Sourcing of reference products, similarity, naming, interchangeability, immunogenicity, traceability, indication extrapolation.
- Where payers incentivise usage of biosimilars.
- The importance of devices to administer biosimilars.
- Which companies are most active in biosimilar development, what are their targets and how far have they reached.
- Where biosimilar prospects are brightest through 2016
- Comprehensive: From patents/data exclusivity via development, manufacturing issues to regulatory requirements, pricing and reimbursement demands, funding provisions and beyond to the realities of the market – it’s all here
- Global: The situation in 27 developed and developing countries – across Europe, the Americas, Asia-Pacific and the Indian subcontinent
- Up-to-date: Includes 2011 sales data and February 2012 proposed FDA guidance
- Fact-filled: Over 60 tables
See the Table of Contents
For more information, see DrugPatentWatch Reports
Exciting Mid-atlantic news — North Carolina has joined Mid Atlantic Bio.
I’ve always enjoyed attending the Mid-Atlantic BIO conference, at it covers a good diversity of biotechnology companies in Maryland and Virginia. There has also been representation from North Carolina in the past, so it’s nice to see that NC has formally joined the group. I look forward to seeing more North Carolina biotechnology companies at future Mid-Atlantic BIO events!
The Journal of Commercial Biotechnology is offering free trial subscriptions for a limited time. Use the free trial subscription form to sign up for a free trial.
The Journal of Commercial Biotechnology, in print since 1994, is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with current issues and industry trends.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Drug Patent Expirations in March 2012
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|GEODON||Pfizer||ziprasidone mesylate||4,831,031||Mar 2, 2012|
|GEODON||Pfizer Inc||ziprasidone hydrochloride||4,831,031||Mar 2, 2012|
|GEODON||Pfizer||ziprasidone hydrochloride||4,831,031||Mar 2, 2012|
|ZOFRAN||Glaxosmithkline||ondansetron hydrochloride||5,344,658*PED||Mar 6, 2012|
|GENESA||Gensia Automedics||arbutamine hydrochloride||5,395,970||Mar 7, 2012|
|NUTROPIN DEPOT||Genentech||somatropin recombinant||5,912,015||Mar 12, 2012|
|LEXAPRO||Forest Labs||escitalopram oxalate||RE34712*PED||Mar 14, 2012|
|AVANDIA||Sb Pharmco||rosiglitazone maleate||5,002,953*PED||Mar 17, 2012|
|AVANDAMET||Sb Pharmco||metformin hydrochloride; rosiglitazone maleate||5,002,953*PED||Mar 17, 2012|
|AVANDARYL||Sb Pharmco||glimepiride; rosiglitazone maleate||5,002,953*PED||Mar 17, 2012|
|BONIVA||Roche||ibandronate sodium||4,927,814||Mar 17, 2012|
|ERAXIS||Vicuron||anidulafungin||6,384,013||Mar 19, 2012|
|ERAXIS||Vicuron||anidulafungin||6,743,777||Mar 19, 2012|
|VALTURNA||Novartis||aliskiren hemifumarate; valsartan||5,399,578||Mar 21, 2012|
|GABITRIL||Cephalon||tiagabine hydrochloride||5,354,760||Mar 24, 2012|
|SEROQUEL||Astrazeneca||quetiapine fumarate||4,879,288*PED||Mar 26, 2012|
|SEROQUEL XR||Astrazeneca||quetiapine fumarate||4,879,288*PED||Mar 26, 2012|
|NUEDEXTA||Avanir Pharms||dextromethorphan hydrobromide; quinidine sulfate||5,206,248||Mar 27, 2012|
|FLOXIN OTIC||Daiichi||ofloxacin||5,401,741||Mar 27, 2012|
|AVALIDE||Sanofi Aventis||hydrochlorothiazide; irbesartan||5,270,317*PED||Mar 30, 2012|
|AVAPRO||Sanofi Aventis Us||irbesartan||5,270,317*PED||Mar 30, 2012|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.
Courtesy of DrugPatentWatch.com